Jane Street
MBRX icon

Jane Street’s Moleculin Biotech MBRX Stock Holding History

Jane Street’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,550
Closed -$74.6K – 12413
2025
Q4 		$74.6K Buy
+22,550
New +$210K ﹤0.01% 10338
2022
Q4 		– Sell
-53
Closed -$21K – 9723
2022
Q3 		$21K Buy
+53
New +$30.7K ﹤0.01% 9188
2019
Q4 		– Sell
-17
Closed -$42K – 5477
2019
Q3 		$42K Buy
+17
New +$43.9K ﹤0.01% 4906
2017
Q3 		– Sell
-5
Closed -$22K – 4822
2017
Q2 		$22K Buy
+5
New +$10.9K ﹤0.01% 4253

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM

Jane Street's MBRX Position: Q1 2026 in Review

Jane Street sold out of Moleculin Biotech (MBRX) in Q1 2026, closing a stake of 22,550 shares — an estimated $74.6K sold.

Jane Street first reported a position in MBRX in Q2 2017 and held it in 4 quarters. The position peaked at $74.6K in Q4 2025. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Jane Street reported no remaining Moleculin Biotech position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 22,550 Moleculin Biotech shares in Q1 2026, an estimated $74.6K.
  • Jane Street first reported a position in Moleculin Biotech in Q2 2017 and held it in 4 quarters.
  • Jane Street's Moleculin Biotech position peaked at $74.6K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.